News|Videos|October 24, 2023
Advancements in Immunotherapy and Novel Therapies for Colorectal Cancer
Shared insight into the latest developments in immunotherapy and novel treatment options for colorectal cancer, including ongoing trials and the pursuit of new targets to enhance the immune response against cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5